{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:00:56Z","timestamp":1784293256741,"version":"3.55.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12325-026-03542-2","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:35:02Z","timestamp":1773336902000},"page":"2182-2201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Budget Impact of Venetoclax for Newly Diagnosed Patients with Acute Myeloid Leukemia Aged\u2009\u2265\u200975 Years or with Comorbidities Precluding Intensive Chemotherapy in the United States"],"prefix":"10.1007","volume":"43","author":[{"given":"Yanqing","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylee","family":"Miu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Montez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglei","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"3542_CR1","doi-asserted-by":"crossref","unstructured":"Liu R, Botteman M. Benchmarking of budget impact results: an updated systematic review of US budget impact analyses. ISPOR, May 7\u201310, 2023, Boston, MA.","DOI":"10.1016\/j.jval.2023.03.2226"},{"issue":"6","key":"3542_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/blood.2024026232","volume":"145","author":"G Huls","year":"2025","unstructured":"Huls G, Woolthuis CM, Schuringa JJ. Menin inhibitors in the treatment of acute myeloid leukemia. Blood. 2025;145(6):561\u20136.","journal-title":"Blood"},{"issue":"5","key":"3542_CR3","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk\u2010stratification, and management. Am J Hematol. 2025;100(5):860\u201391.","journal-title":"Am J Hematol"},{"key":"3542_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"key":"3542_CR5","unstructured":"National Cancer Institute. Acute myeloid leukemia treatment (PDQ\u00ae)\u2014Health Professional Version. 2024. https:\/\/www.cancer.gov\/types\/leukemia\/hp\/adult-aml-treatment-pdq#_1. Accessed 1 Oct 2024."},{"key":"3542_CR6","unstructured":"National Cancer Institute. Cancer stat facts: leukemia\u2014acute myeloid leukemia (AML). https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html. Accessed 25 May 2025."},{"key":"3542_CR7","unstructured":"American Cancer Society. Key statistics for acute myeloid leukemia (AML). https:\/\/www.cancer.org\/cancer\/types\/acute-myeloid-leukemia\/about\/key-statistics.html. Accessed 25 May 2025."},{"issue":"1","key":"3542_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01346-1","volume":"15","author":"N Gangat","year":"2025","unstructured":"Gangat N, Dinardo CD. Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms. Blood Cancer J. 2025;15(1):139.","journal-title":"Blood Cancer J"},{"issue":"11","key":"3542_CR9","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1007\/s12325-024-02947-1","volume":"41","author":"U Borate","year":"2024","unstructured":"Borate U, Seiter K, Potluri R, Mazumder D, Chevli M, Prebet T, et al. Healthcare utilization and costs among patients with acute myeloid leukemia receiving oral azacitidine maintenance therapy versus no maintenance: a US claims database study. Adv Ther. 2024;41(11):4049\u201364.","journal-title":"Adv Ther"},{"key":"3542_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/JBM.S279736","volume":"12","author":"A Forsythe","year":"2021","unstructured":"Forsythe A, Sandman K. What does the economic burden of acute myeloid leukemia treatment look like for the next decade? An analysis of key findings, challenges and recommendations. J Blood Med. 2021;12:245\u201355.","journal-title":"J Blood Med"},{"issue":"7","key":"3542_CR11","first-page":"849","volume":"26","author":"BJ Pandya","year":"2020","unstructured":"Pandya BJ, Chen CC, Medeiros BC, McGuiness CB, Wilson SD, Walsh EH, et al. Economic and clinical burden of acute myeloid leukemia episodes of care in the United States: a retrospective analysis of a commercial payer database. J Manag Care Spec Pharm. 2020;26(7):849\u201359.","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"3542_CR12","first-page":"980","volume":"28","author":"M Choi","year":"2022","unstructured":"Choi M, Song J, Bui CN, Ma E, Chai X, Yin L, et al. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy. J Manag Care Spec Pharm. 2022;28(9):980\u20138.","journal-title":"J Manag Care Spec Pharm"},{"key":"3542_CR13","unstructured":"American Cancer Society. Typical treatment of acute myeloid leukemia (except APL). https:\/\/www.cancer.org\/cancer\/types\/acute-myeloid-leukemia\/treating\/typical-treatment-of-aml.html. Accessed 1 Oct 2024."},{"key":"3542_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719882822","volume":"10","author":"G Richard-Carpentier","year":"2019","unstructured":"Richard-Carpentier G, DiNardo CD. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Ther Adv Hematol. 2019;10:2040620719882822.","journal-title":"Ther Adv Hematol"},{"issue":"15","key":"3542_CR15","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1002\/cncr.28129","volume":"119","author":"MS Thein","year":"2013","unstructured":"Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer. 2013;119(15):2720\u20137.","journal-title":"Cancer"},{"key":"3542_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720913010","volume":"11","author":"N Vey","year":"2020","unstructured":"Vey N. Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia. Ther Adv Hematol. 2020;11:2040620720913010.","journal-title":"Ther Adv Hematol"},{"key":"3542_CR17","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: VENCLEXTA (venetoclax). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208573s027lbl.pdf. Accessed 11 Nov 2025."},{"key":"3542_CR18","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Acute Myeloid Leukemia. Version 2.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed May 2025. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"key":"3542_CR19","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: TIBSOVO (ivosidenib). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/211192_s008lbl.pdf. Accessed 25 May 2025."},{"key":"3542_CR20","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: DAURISMO (glasdegib). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/210656s002s004lbl.pdf. Accessed 23 June 2020."},{"key":"3542_CR21","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: MYLOTARG (gemtuzumab ozogamicin). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761060lbl.pdf. Accessed 25 May 2025."},{"issue":"30","key":"3542_CR22","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.20.00572","volume":"38","author":"CC Chua","year":"2020","unstructured":"Chua CC, Roberts AW, Reynolds J, Fong CY, Ting SB, Salmon JM, et al. Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase ib dose-escalation study of venetoclax combined with modified intensive chemotherapy. J Clin Oncol. 2020;38(30):3506\u201317.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3542_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"supplement 1","key":"3542_CR24","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/blood-2023-182045","volume":"142","author":"A Venditti","year":"2023","unstructured":"Venditti A, Hou J-Z, Fenaux P, Jonas BA, Vrhovac R, Montesinos P, et al. Outcomes in chemotherapy-ineligible elderly patients with newly diagnosed acute myeloid leukemia treated with venetoclax plus azacitidine: a pooled analysis. Blood. 2023;142(supplement 1):2886.","journal-title":"Blood"},{"issue":"4","key":"3542_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615\u201324.","journal-title":"Am J Hematol"},{"issue":"2","key":"3542_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216\u201328.","journal-title":"Lancet Oncol"},{"issue":"15","key":"3542_CR27","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA Jr., Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol. 2019;37(15):1277\u201384.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3542_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317.","journal-title":"Blood"},{"issue":"2","key":"3542_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol. 2021;96(2):208\u201317.","journal-title":"Am J Hematol"},{"key":"3542_CR30","unstructured":"Genentech & AbbVie. Venclexa: Remission assessment and AR management. https:\/\/www.venclextahcp.com\/aml\/dosing-and-administration\/assessment.html. Accessed 4 Nov 2025."},{"key":"3542_CR31","unstructured":"National Institute of Health. NIH SEER*Explorer: An interactive website for SEER cancer statistics. Acute myeloid leukemia (AML) recent trends in SEER age-adjusted incidence rates, 2000\u20132018. 2022. https:\/\/seer.cancer.gov\/explorer\/. Accessed 17 Feb 2022."},{"key":"3542_CR32","unstructured":"United States Census Bureau. Annual estimates of the resident population for selected age groups by sex for the United States. 2019. https:\/\/www.census.gov\/data\/tables\/time-series\/demo\/popest\/2010s-national-detail.html. Accessed 19 June 2020."},{"issue":"Suppl 1","key":"3542_CR33","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/j.clml.2011.02.003","volume":"11","author":"G Juliusson","year":"2011","unstructured":"Juliusson G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. Clin Lymphoma Myeloma Leuk. 2011;11(Suppl 1):S54\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"3542_CR34","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/ajh.23576","volume":"88","author":"JH Yoon","year":"2013","unstructured":"Yoon JH, Cho BS, Kim HJ. Outcomes of elderly de novo acute myeloid leukemia treated by a risk\u2010adapted approach based on age, comorbidity, and performance status. Am J Hematol. 2013;88(12):1074\u201381.","journal-title":"Am J Hematol"},{"issue":"21","key":"3542_CR35","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, Thomas X, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670\u20137.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3542_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1182\/blood.2019002140","volume":"135","author":"GJ Roboz","year":"2020","unstructured":"Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463\u201371.","journal-title":"Blood"},{"issue":"9","key":"3542_CR37","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","volume":"34","author":"S Amadori","year":"2016","unstructured":"Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34(9):972\u201381.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3542_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","volume":"33","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379\u201389.","journal-title":"Leukemia"},{"issue":"20","key":"3542_CR39","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-19-0365","volume":"25","author":"KJ Norsworthy","year":"2019","unstructured":"Norsworthy KJ, By K, Subramaniam S, Zhuang L, Del Valle PL, Przepiorka D, et al. FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia. Clin Cancer Res. 2019;25(20):6021\u20135.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"3542_CR40","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386(16):1519\u201331.","journal-title":"N Engl J Med"},{"issue":"24","key":"3542_CR41","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137\u201345.","journal-title":"Blood"},{"issue":"4","key":"3542_CR42","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3109\/10428194.2014.951845","volume":"56","author":"J He","year":"2015","unstructured":"He J, Xiu L, De Porre P, Dass R, Thomas X. Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of randomized phase III study. Leuk Lymphoma. 2015;56(4):1033\u201342.","journal-title":"Leuk Lymphoma"},{"key":"3542_CR43","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.1016\/j.clml.2019.07.114","volume":"19","author":"ES Wang","year":"2019","unstructured":"Wang ES, Heuser M, Montesinos P, Sekeres MA, Merchant A, Olive CP, et al. Glasdegib with LDAC in newly diagnosed patients with acute myeloid leukemia (AML) unsuitable for intensive chemotherapy: effects on transfusions and marrow recovery vs LDAC alone. Clin Lymphoma Myeloma Leuk. 2019;19:S230.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3542_CR44","unstructured":"United States Bureau of Economic Analysis. Personal Consumption Expenditures Price Index. https:\/\/www.bea.gov\/data\/personal-consumption-expenditures-price-index. Accessed 25 May 2025."},{"key":"3542_CR45","unstructured":"Pelech D. Congressional Budget Office. An analysis of private-sector prices for physicians' services. Working paper 2018-01. 2018. https:\/\/www.cbo.gov\/system\/files\/115th-congress-2017-2018\/workingpaper\/53441-workingpaper.pdf. Accessed 25 May 2025."},{"key":"3542_CR46","unstructured":"Truven REDBOOK Online. Wholesale acquisition cost. 2024. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian. Accessed 22 May 2024."},{"key":"3542_CR47","unstructured":"CMS Physician Fee Schedule. Centers for Medicare and Medicaid Services finalizes 2020 Medicare hospital outpatient payment policy. http:\/\/www.aabb.org\/advocacy\/reimbursementinitiatives\/Documents\/OPPS-2020-Proposed-Rule-Summary.pdf. Accessed 24 June 2020."},{"key":"3542_CR48","unstructured":"Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP). Nationwide Inpatient Sample (NIS). 2016. http:\/\/hcupnet.ahrq.gov\/. Accessed 20 June 2020."},{"key":"3542_CR49","unstructured":"National Institute for Health and Care Excellence. Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts. TA399. https:\/\/www.nice.org.uk\/guidance\/ta399. Accessed 25 May 2025."},{"key":"3542_CR50","doi-asserted-by":"crossref","unstructured":"LeBlanc T, Seetasith A, Choi M, Surinach A, Tu M, Montez M, et al. Healthcare resource utilization and total cost of care in older patients with acute myeloid leukemia ineligible for intensive chemotherapy. American Society of Clinical Oncology Quality Care Symposium (ASCO-QCS) Annual Meeting; October 9\u201310, 2020; virtual.","DOI":"10.1200\/JCO.2020.38.29_suppl.72"},{"issue":"1","key":"3542_CR51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5\u201314.","journal-title":"Value Health"},{"issue":"1","key":"3542_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0295798","volume":"19","author":"A Palacios","year":"2024","unstructured":"Palacios A, Espinola N, Gonzalez JM, Rojas-Roque C, Rivas MM, Kanevski D, et al. Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina. PLoS ONE. 2024;19(1):e0295798.","journal-title":"PLoS ONE"},{"issue":"1","key":"3542_CR53","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40273-020-00976-6","volume":"39","author":"C Mamolo","year":"2021","unstructured":"Mamolo C, Welch V, Walter RB, Cappelleri JC, Brockbank J, Cawson M, et al. Budget impact analysis of gemtuzumab ozogamicin for the treatment of CD33-positive acute myeloid leukemia. Pharmacoeconomics. 2021;39(1):121\u201331.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"3542_CR54","first-page":"380","volume":"11","author":"IS Jensen","year":"2018","unstructured":"Jensen IS, Wu E, Sacks NC, Cyr PL, Chung KC. Budget impact analysis of using daunorubicin-cytarabine liposome in patients with newly diagnosed therapy-related AML or AML and myelodysplasia-related changes. Am Health Drug Benefits. 2018;11(7):380\u20136.","journal-title":"Am Health Drug Benefits"},{"key":"3542_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101523","volume":"25","author":"A Bhatt","year":"2022","unstructured":"Bhatt A, Powell K, Prasad V. The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: how many limitations is too many? Transl Oncol. 2022;25:101523.","journal-title":"Transl Oncol"},{"issue":"2","key":"3542_CR56","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbmt.2007.10.010","volume":"14","author":"A Saito","year":"2008","unstructured":"Saito A, Cutler C, Zahrieh D, Soiffer R, Ho V. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008;14(2):197\u2013207.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03542-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03542-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03542-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:37:33Z","timestamp":1778229453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03542-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3542"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03542-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This budget impact model used previously collected or published data; thus, ethical review was not required. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Yanqing\u00a0Xu, Janet Nguyen, and Kaylee Miu are employees of AbbVie, Inc. and hold stock\/options. Chia-Wei Lin and Melissa Montez are employees of Genentech, Inc., and hold stock\/options of Roche Holding. Xinglei Chai and Xin Chen are employees of Analysis Group, Inc., which has received consulting fees from Genentech, Inc. and AbbVie, Inc., for the conduct of this study. Thomas W. LeBlanc is a Scholar in Clinical Research of Blood Cancer United, and has received honoraria for consulting\/advisory boards from AbbVie, Agios\/Servier, Apellis, Astellas, BMS\/Celgene, Daiichi-Sankyo, Genentech, Geron, Gilead, GSK, Lilly, Menarini-Stemline, Novartis, Novo Nordisk, Pfizer, Syndax, and Taiho; speaking related honoraria from AbbVie, Agios\/Servier, Astellas, BMS\/Celgene, Daiichi-Sankyo, Geron, GSK, Incyte, Menarini-Stemline and Rigel; equity interest in Dosentrx and ThymeCare (stock options in privately-held companies); royalties from UpToDate; and research funding from AbbVie, AstraZeneca, BMS, Deverra Therapeutics\/Coeptis, GSK, Jazz Pharmaceuticals, and Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}